A PET [positron emission tomography] study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2014
At a glance
- Drugs GSK 239512 (Primary)
- Indications Dementia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual end date changed from Apr 2008 to Mar 2008 as reported by Clinicaltrials.gov.
- 15 Oct 2008 Actual start date changed from Feb 2007 to Mar 2007 as reported by Clinicaltrials.gov.